Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetilar is a topical cream formulated primarily with cetylated fatty acids (CFAs) and menthol, designed for the relief of joint, muscle, and tendon pain. Its mechanism of action is based on the ability of CFAs—fatty acids esterified with cetyl alcohol—to penetrate the skin barrier, stabilize and lubricate cell membranes, reduce inflammation, and support recovery in musculoskeletal tissues. The product also contains menthol (1.4%), which provides a topical analgesic effect by activating cold-sensitive receptors in the skin to temporarily relieve minor aches and pains. Cetilar is indicated for use in therapeutic massage to improve joint function, mobility after injury or surgery (including osteoarthritis), rehabilitation following inflammatory or traumatic events, as well as sports injuries[1][2][3][4][5][7][9]. It is developed by PharmaNutra S.p.A., an Italian company specializing in nutritional supplements and medical devices[6][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetilar.